Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
Zane Jaunmuktane,Simon Mead,Simon Mead,Matthew Ellis,Jonathan D. F. Wadsworth,Jonathan D. F. Wadsworth,Andrew J. Nicoll,Andrew J. Nicoll,Joanna Kenny,Francesca Launchbury,Jacqueline M. Linehan,Angela Richard-Loendt,A. Sarah Walker,Peter Rudge,John Collinge,John Collinge,Sebastian Brandner,Sebastian Brandner +17 more
Reads0
Chats0
TLDR
The marked deposition of parenchymal and vascular Aβ in these relatively young patients with iCJD, in contrast with other prion disease patients and population controls, is consistent with iatrogenic transmission of Aβ pathology in addition to CJD and suggests that healthy exposed individuals may also be at risk of i atrogenic Alzheimer’s disease and cerebral amyloid angiopathy.Abstract:
More than two hundred individuals developed Creutzfeldt-Jakob disease (CJD) worldwide as a result of treatment, typically in childhood, with human cadaveric pituitary-derived growth hormone contaminated with prions. Although such treatment ceased in 1985, iatrogenic CJD (iCJD) continues to emerge because of the prolonged incubation periods seen in human prion infections. Unexpectedly, in an autopsy study of eight individuals with iCJD, aged 36-51 years, in four we found moderate to severe grey matter and vascular amyloid-β (Aβ) pathology. The Aβ deposition in the grey matter was typical of that seen in Alzheimer's disease and Aβ in the blood vessel walls was characteristic of cerebral amyloid angiopathy and did not co-localize with prion protein deposition. None of these patients had pathogenic mutations, APOE e4 or other high-risk alleles associated with early-onset Alzheimer's disease. Examination of a series of 116 patients with other prion diseases from a prospective observational cohort study showed minimal or no Aβ pathology in cases of similar age range, or a decade older, without APOE e4 risk alleles. We also analysed pituitary glands from individuals with Aβ pathology and found marked Aβ deposition in multiple cases. Experimental seeding of Aβ pathology has been previously demonstrated in primates and transgenic mice by central nervous system or peripheral inoculation with Alzheimer's disease brain homogenate. The marked deposition of parenchymal and vascular Aβ in these relatively young patients with iCJD, in contrast with other prion disease patients and population controls, is consistent with iatrogenic transmission of Aβ pathology in addition to CJD and suggests that healthy exposed individuals may also be at risk of iatrogenic Alzheimer's disease and cerebral amyloid angiopathy. These findings should also prompt investigation of whether other known iatrogenic routes of prion transmission may also be relevant to Aβ and other proteopathic seeds associated with neurodegenerative and other human diseases.read more
Citations
More filters
Journal ArticleDOI
The amyloid hypothesis of Alzheimer's disease at 25 years
Dennis J. Selkoe,John Hardy +1 more
TL;DR: In a recent study, this article showed that low cerebrospinal fluid (CSF) Aβ42 and amyloid-PET positivity precede other AD manifestations by many years.
Journal ArticleDOI
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Justin M. Long,David M. Holtzman +1 more
TL;DR: Recent advances in the understanding of AD pathobiology are reviewed and current treatment strategies are discussed, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.
Journal ArticleDOI
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Bengt Winblad,Bengt Winblad,Philippe Amouyel,Sandrine Andrieu,Clive Ballard,Carol Brayne,Henry Brodaty,Angel Cedazo-Minguez,Bruno Dubois,David Edvardsson,David Edvardsson,Howard Feldman,Laura Fratiglioni,Giovanni B. Frisoni,Serge Gauthier,Jean Georges,Caroline Graff,Caroline Graff,Khalid Iqbal,Frank Jessen,Frank Jessen,Gunilla Johansson,Linus Jönsson,Miia Kivipelto,Miia Kivipelto,Martin Knapp,Francesca Mangialasche,René J. F. Melis,Agneta Nordberg,Agneta Nordberg,Marcel G. M. Olde Rikkert,Chengxuan Qiu,Thomas P. Sakmar,Thomas P. Sakmar,Philip Scheltens,Lon S. Schneider,Reisa A. Sperling,Lars O. Tjernberg,Gunhild Waldemar,Anders Wimo,Henrik Zetterberg,Henrik Zetterberg +41 more
TL;DR: This poster aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the physical and cognitive properties of Alzheimer's disease and other dementias.
Journal ArticleDOI
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
TL;DR: It is proposed that abnormal systemic changes might not only develop secondary to brain dysfunction but might also affect AD progression, suggesting that the interactions between the brain and the periphery have a crucial role in the development and progression of AD.
Journal ArticleDOI
The activities of amyloids from a structural perspective
TL;DR: Amyloids are composed of pairs of tightly interacting, many stranded and repetitive intermolecular β-sheets, which form the cross-β-sheet structure which enables amyloids to grow by recruitment of the same protein and its repetition can transform a weak biological activity into a potent one through cooperativity and avidity.
References
More filters
Journal ArticleDOI
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Suzanne S. Mirra,Albert Heyman,Daniel W. McKeel,S. M. Sumi,Barbara J. Crain,L. M. Brownlee,Vogel Fs,James P. Hughes,van Belle G,Leonard Berg +9 more
TL;DR: The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects, which provides neuropathologic definitions of such terms as “definite Alzheimer's disease” (AD), “probable AD,” “possible AD” and “normal brain” to indicate levels of diagnostic certainty.
Journal Article
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease.
Journal ArticleDOI
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
TL;DR: Aβ-deposition in the entire brain follows a distinct sequence in which the regions are hierarchically involved and expands anterogradely into regions that receive neuronal projections from regions already exhibiting Aβ.
Book ChapterDOI
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Journal ArticleDOI
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.
TL;DR: To better meet the demands of routine laboratories this procedure is revised here by adapting tissue selection and processing to the needs of paraffin-embedded sections and by introducing a robust immunoreaction (AT8) for hyperphosphorylated tau protein that can be processed on an automated basis.
Related Papers (5)
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.
Melanie Meyer-Luehmann,Janaky Coomaraswamy,Tristan Bolmont,Tristan Bolmont,Stephan A. Kaeser,Claudia Schaefer,Ellen Kilger,Anton Neuenschwander,Dorothee Abramowski,Peter Frey,Anneliese L. Jaton,Jean-Marie Vigouret,Paolo Paganetti,Dominic M. Walsh,Paul M. Mathews,Jorge Ghiso,Matthias Staufenbiel,Lary C. Walker,Mathias Jucker,Mathias Jucker +19 more